Previous Close | 0.5143 |
Open | 0.5200 |
Bid | 0.5361 x 1100 |
Ask | 0.5379 x 1300 |
Day's Range | 0.5031 - 0.5393 |
52 Week Range | 0.4900 - 1.9400 |
Volume | |
Avg. Volume | 3,445,950 |
Market Cap | 183.281M |
Beta (5Y Monthly) | 3.00 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Said its Aurora Europe GmbH subsidiary and Ethypharm have once again been selected by the French General ...
Aurora Cannabis (NASDAQ: ACB) has been struggling for years. The stock is trading down to well under $1 per share, and another reverse stock split is inevitable for the company. Aurora Cannabis' stock price fell 96% over the past three years.
Investors looking to add quality growth stocks to their equity portfolio can consider buying Well Health right now. The post 2 TSX Stocks to Buy This Month and 1 to Avoid appeared first on The Motley Fool Canada.
One was once a favorite among cannabis investors, but the other could become the top cannabis contender.
Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is more growth coming? The post What’s Happening With Cannabis Stocks in May 2023? appeared first on The Motley Fool Canada.
Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth prospects and fundamentals. The post Aurora Cannabis: Time to Light Up Your Portfolio? appeared first on The Motley Fool Canada.
It's been roughly five years since Canada legalized cannabis, and it's been an unpleasant ride for investors in Aurora Cannabis (NASDAQ: ACB), one of Canada's leading growers and operators. The company became a penny stock after surging to over $120 per share in 2018. While some may hope for a tremendous comeback story, sometimes a business model just isn't good.
Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio. The post 1 Marijuana Stock I’d Buy Over Aurora Cannabis appeared first on The Motley Fool Canada.
Marijuana stocks have fallen out of favor in the last two years. The Canadian producers Aurora Cannabis (NASDAQ: ACB) and Tilray Brands (NASDAQ: TLRY) are two of the most popular marijuana companies. Aurora Cannabis has been investors' favorite among pot stocks for a while.
Today announced a fresh lineup of innovative products. Coming soon to patients at Aurora Medical and ...
April 20th has a special significance for the cannabis industry. Three of those companies have especially attracted investors' attention in recent years -- Aurora Cannabis (NASDAQ: ACB), Curaleaf Holdings (OTC: CURLF), and SNDL (NASDAQ: SNDL) (formerly known as Sundial Growers). Aurora Cannabis is the worst of the group, with its share price plunging more than 80%.
Despite losing most of their value, these former Wall Street darlings have been popular buys among billionaire money managers.
The Canadian government's decision to license over 1,000 cannabis producers, along with its inability to rein in black market operators, has been an unmitigated disaster for the country's top legal cultivators. Despite billions of dollars being spent on state-of-the-art cultivation facilities, brick-and-mortar retail outlets, and virtual storefronts, Canada's largest cannabis companies have been losing money at an alarming rate due to a vast oversupply of product in the country. In turn, profit margins have cratered across the industry, spurring some notable cannabis companies like Aurora Cannabis (NASDAQ: ACB), SNDL, and Tilray Brands to diversify into non-cannabis businesses like alcohol and vegetables in an effort to become cash-flow-positive.
Here's why cannabis stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets for TSX investors. The post Are Cannabis Stocks a Good Buy in April 2023? appeared first on The Motley Fool Canada.
Marijuana stocks have performed poorly over the last two years. Cannabis analytics firm BDSA estimates that global cannabis sales will reach $57 billion by 2026, a 13% annual growth forecast from $30 billion in 2021, with bulk of this growth expected to be driven by the Canadian and American markets. Investment opportunities seem lucrative, and investors with a higher risk appetite might stand to profit handsomely in the long run in this volatile industry.
Canadian marijuana company Aurora Cannabis (NASDAQ: ACB) is having another bad day. The pot seller's shares were down by a noteworthy 4.34% on moderate volume as of 2:05 p.m. ET on Monday. Since the start of the year, Aurora's stock has now shed 27.5% of its value, and the share price has fallen well below the Nasdaq's $1 bid requirement, triggering a noncompliance notice from the exchange last month.
Key Takeaways; Cannabis Sector Aurora announced the repurchase of convertible senior notes worth approximately $47 million, saving the company $2.6 million in annualized interest payments. Jushi Holdings reported preliminary Q4 and record full year 2022 financial results. Curaleaf announced $20 million acquisition in Key Takeaways; Psychedelic Sector Awakn’s proprietary treatment protocol for alcohol use disorder […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared fi
Restructuring and changes in strategy are moves that businesses often deploy when they're facing challenges and headwinds. While Aurora Cannabis (NASDAQ: ACB) has been slashing costs and changing its operations in recent years, the company isn't out of the woods by any stretch. Among the biggest moves that Aurora has made in recent years has been to shift its business more toward medical marijuana.
Aurora Cannabis (NASDAQ: ACB) is one of the few Canadian cannabis retailers that is still seeing revenue growth, despite price compression and illegal sales negatively impacting the industry. The company is still losing money, but it appears to be edging its way toward profitability. Aurora's path to success includes branching out to international markets while focusing more on medical marijuana sales at home.
With fears of economic turbulence receding, Aurora Cannabis, Canopy Growth, and Organigram rebounded from their Monday declines.
Aurora Cannabis (NASDAQ: ACB) hit a long-awaited milestone in its most recent earnings results: adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) profitability. Here's a closer look at how Aurora achieved an adjusted EBITDA profit, and whether that should impact your decision to buy the stock or not. Since it's a non-GAAP (adjusted) number, a company can make adjustments to that number that it otherwise wouldn't be able to make to net income.
The cannabis industry in Canada hasn't been in good shape for some time. Growth is almost nonexistent, profits are elusive, and stock prices of marijuana producers have been nosediving. What's particularly telling are the moves of two of the industry's leaders, Aurora Cannabis (NASDAQ: ACB) and Canopy Growth (NASDAQ: CGC).
One sector that's undoubtedly gone from bubble territory to flat-out deflated is cannabis. Many producers saw valuations skyrocket upon the federal legalization of cannabis in Canada in late 2018. U.S.-based multi-state operators (MSOs) like Curaleaf (OTC: CURLF) have certainly had a rough go over the past two years.
Aurora Cannabis stock is down 99% from all-time highs. Is ACB stock a buy, sell, or hold in March 2023? The post What’s Next for Aurora Cannabis Stock? appeared first on The Motley Fool Canada.
Suppose you bought $10,000 of Aurora Cannabis (NASDAQ: ACB) stock five years ago and held onto those shares. With that abysmal performance, you might think making a case for investing in Aurora Cannabis today would be an exercise in futility. If these four words are true, buying the heavily beaten-down marijuana stock could pay off nicely.